Atossa Therapeutics, Inc.

What they do

Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for oncology and rare diseases. Its lead drug candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator/degrader currently in Phase 2 development for breast cancer and other indications. The company holds seven U.S. and 16 international patents for (Z)-endoxifen, with protection expected through at least November 17, 2038.

Revenue drivers

• No approved products — The company has no commercial products and has not generated meaningful revenue; annual revenue was $1,758 in 2025 and near zero in recent quarters.

Recent performance

For the fiscal year 2025, Atossa reported a net loss of $34.8 million, with diluted EPS of $-4.04. Operating cash flow was negative $29.8 million. The company had cash and equivalents of $26.1 million and total assets of $32.3 million as of June 30, 2026. Revenue has been negligible historically, with recent quarterly revenue reported as zero in 2016.

Strategy

Atossa's strategy is to advance (Z)-endoxifen through clinical studies, including potential partnerships, and to opportunistically add programs in high unmet medical need areas through acquisition, collaboration, or internal development. The company is evaluating (Z)-endoxifen across the ER+/HER2- breast cancer treatment continuum, including neoadjuvant, adjuvant, and breast density reduction. Additionally, it is exploring applications in rare diseases such as Duchenne Muscular Dystrophy, women carriers of DMD, and McCune-Albright Syndrome. The company has been presenting data at conferences (AACR, ASCO) and publishing in peer-reviewed journals to support its clinical and scientific foundation.

Risks

• Clinical-stage uncertainty — As a clinical-stage company, Atossa faces significant risks from potential clinical trial failures, regulatory delays, or adverse safety data.
• No revenue — With no approved products and minimal historical revenue, the company depends entirely on external capital to fund operations.
• Financing dilution — The company raised capital through a registered direct offering in 2026, which may dilute existing shareholders.
• Regulatory approval risk — The FDA and foreign regulators must approve (Z)-endoxifen for any indication; obtaining approval is uncertain and costly.

Outlook

Management is optimistic about (Z)-endoxifen's potential across multiple indications, citing recent publications and conference presentations. They believe the drug could address unmet needs in breast cancer and rare pediatric diseases. The company plans to continue advancing its clinical programs and exploring new opportunities, but faces a high cash burn rate relative to its cash position.